Gabriela Gruia

CIK: 0001860326

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

APRE

Aprea Therapeutics, Inc.

Director

TCRX

TScan Therapeutics, Inc.

Director

MTEM

Molecular Templates, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

APRE
Aprea Therapeutics, Inc.
Jun 16, 2026
Award(A)
Direct
3.1K shares-
TCRX
TScan Therapeutics, Inc.
May 20, 2026
Award(A)
Stock Option (Right to Buy)
Direct
67K shares-
TCRX
TScan Therapeutics, Inc.
Jun 30, 2025
Award(A)
Stock Option (Right to Buy)
Direct
67K shares-
APRE
Aprea Therapeutics, Inc.
Jun 5, 2025
Award(A)
Direct
1K shares-
MTEM
Molecular Templates, Inc.
Sep 27, 2024
Award(A)
Stock Option (right to buy)
Direct
1K shares-

		Type	Shares	Price		Ownership
Jun 16, 2026	APRE Aprea Therapeutics, Inc.	Award(A)	3,135	-	$0	Direct
May 20, 2026	TCRX TScan Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	67,000	-	-	Direct
Jun 30, 2025	TCRX TScan Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	67,000	-	-	Direct
Jun 5, 2025	APRE Aprea Therapeutics, Inc.	Award(A)	1,045	-	-	Direct
Sep 27, 2024	MTEM Molecular Templates, Inc.	Award(A) Stock Option (right to buy)	1,000	-	-	Direct

1-5 of 5 transactions

About Gruia Gabriela

Gruia Gabriela (SEC CIK 0001860326) files insider reports with the SEC as Director of Aprea Therapeutics, Inc. (APRE), Director of TScan Therapeutics, Inc. (TCRX) and Director of Molecular Templates, Inc. (MTEM).

Signal8 holds 5 ownership filings by Gruia Gabriela, all Form 4s, filed between Sep 30, 2024 and Jun 17, 2026. Those filings report 5 transactions, from Sep 27, 2024 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Gruia Gabriela's filings is in DOYLESTOWN, PA.

Recent filings by Gruia Gabriela

Jun 16, 2026: Grant or award of APRE shares (Form 4, code A).
May 20, 2026: Grant or award of TCRX derivative securities (Form 4, code A).
Jun 30, 2025: Grant or award of TCRX derivative securities (Form 4, code A).
Jun 5, 2025: Grant or award of APRE shares (Form 4, code A).
Sep 27, 2024: Grant or award of MTEM derivative securities (Form 4, code A).

Other insiders filing for Aprea Therapeutics, Inc. (APRE)

Grissinger Michael, Director
Peters Richard, Director
HENNEMAN JOHN B III, Director
BIZZARI JEAN-PIERRE, Director
Duey Marc, Director
Pamukcu Rifat, Director

How to read Form 4 transaction codes